HEALTH TECHNOLOGY

Amino Named NCPA Awarded Vendor for Healthcare Navigation

Amino | September 16, 2021

Amino, a leading healthcare guidance platform, today announced that the company has been named an awarded vendor for digital healthcare navigation by the National Cooperative Purchasing Alliance (NCPA), a leading national government purchasing cooperative. NCPA members can now seamlessly add Guidance, Amino's groundbreaking healthcare search and appointment booking platform, to their health benefits package to help employees and their dependents make smarter decisions about where to get care.

Navigating healthcare choices can be confusing and stressful for employees, but Amino simplifies the process. We're excited to offer this technology to our members and their employees, and we look forward to seeing the impact Amino has on healthcare quality, cost, and experience over the next few years.

Mike Muscara, NCPA Director of Member and Vendor Support

Amino's proprietary recommendation engine uses insights from claims, quality measures, and other healthcare data to identify Smart Matches—high quality, cost-effective providers that are in-network for an employee's health plan. The platform guides users to these top 10-15% of providers based on their individual health needs, which reduces wasteful spending and improves care quality.

Amino Guidance also helps employees find and use relevant employer-sponsored health benefits such as telemedicine, chronic condition management programs, and behavioral health services when they search for a relevant health topic, increasing program utilization and ROI.

Amino already partners with several public organizations to provide healthcare guidance services, including states, local governments, and schools. Through our partnership with NCPA, we look forward to helping even more public sector clients improve their employees' healthcare experience with simple, convenient technology that helps them get the most value out of their health plans and benefits.

Amino CEO David Vivero

About Amino
Amino empowers patients to evaluate their healthcare options and make smart decisions about their care. Our digital healthcare guidance platform provides a fast, easy way to search for providers, book appointments, and access employer-sponsored health benefits. By guiding members to high-value care, Amino improves outcomes and saves employers and their employees time and money. To learn more, visit amino.com.

 

About NCPA
NCPA is a leading national government purchasing cooperative working to reduce the cost of goods and services by leveraging the purchasing power of public agencies in all 50 states. NCPA utilizes state of the art procurement resources and solutions that result in cooperative purchasing contracts that ensure all public agencies are receiving products and services of the highest quality at the lowest prices. There are over 90,000 agencies nationwide from both the public and nonprofit sectors that are eligible to utilize NCPA's cooperative purchasing contracts.

Spotlight

The World Health Organization (WHO) has called the West Africa Ebola outbreak an international public health emergency. This infographic presents the public health benefits of using ICD-10 in the fight against Ebola. As the fourth American Ebola patient, a physician serving in West Africa, was flown to the U.S. for emergency care this week, I was reminded that public health also wins from the implementation of ICD-10. According to World Health Organization (WHO), the latest Ebola outbreak has killed almost 2,300 people in five West African countries. Medical workers have been hit hard by the Ebola epidemic.


Other News
FUTURE OF HEALTHCARE

Omega Healthcare Acquires Reventics, a Physician Focused CDI and RCM Company

Omega Healthcare | March 09, 2022

Omega Healthcare, a leading healthcare management solutions partner supporting the broad healthcare ecosystem, today announced its acquisition of Reventics, aDenver, CObased company. Reventics is a clinical documentation improvement ("CDI") and revenue cycle management ("RCM") solutions provider that delivers Provider Engagement Solutions to enhance physician reimbursement and compliance, while improving clinical quality measures. This acquisition enables Omega Healthcare to expand its core coding and RCM offering by leveraging Reventics' proprietary cloud native platforms for CDI and RCM - RevCDI and RevMAX - along with expert clinical resources to drive improved outcomes for its clients. The transaction is part of Omega Healthcare's strategic growth plan to expand its existing CDI capabilities through technology-driven solutions, giving Omega exceptional scale and proficiency in this specialized competency. "Reventics brings to our organization clinical excellence, analytic capabilities, and new age technologies to complement Omega's existing technology and automation services. Not only is this a strategic fit that will benefit our clients, but we will be able to expand our CDI and RCM capabilities through this acquisition, while increasing our AI capabilities as well." Anurag Mehta, CEO of Omega Healthcare "We see our core values of "client first" approach reflected in Omega's own philosophy and are excited by how our clients could benefit from the larger enterprise and its extensive capabilities. We believe the client partnerships we currently enjoy will only be strengthened through this transaction." saysArnab Sen, CEO of Reventics. " "Omega is excited to welcome the Reventics team and is eagerly looking forward to creating enhanced value for its customers under the combined leadership" addedSumithra Gomatam, Executive Chair of Omega. Anurag Mehtawill continue to serve as the CEO of the combined entity. About Omega Healthcare Founded in 2003, Omega helps payers, providers, and pharmaceutical companies eliminate administrative burdens, accelerate cash flow, and reduce health management costs while enhancing patient care. The company streamlines medical billing, coding, and collections processes and provides virtual nursing services, including triage, care continuation, clinical documentation improvement, and re-admittance avoidance. Combining the largest medical coding staff in the world with proprietary technology, analytics, and automation capabilities, Omega provides the most comprehensive outsourced solutions in the industry and is ranked among the top revenue cycle management business process services by industry analysts. Backed by the Private Equity business within Goldman Sachs Asset Management and Everstone Group, Omega has more than 20,000 employees acrossthe United States,India,the Philippines. About Reventics Reventics is a physician-focusedclinical documentation improvement (CDI)andrevenue cycle management (RCM)company. The company is changing the way the industry thinks about CDI and RCM by placing the provider at the center of its solutions. From the AI that powers Reventics' products to its physician-led delivery approach, Reventics drives an unrelenting focus on clinicians, to improve their operational and financial outcomes. Reventics' approach is based on using itsto deliver Provider Engagement Solutions that enhance physician reimbursement and compliance while improving clinical quality measures.

Read More

MEDICAL DEVICES

CeloNova Announces New Strategic Direction Focused on Creating Partnership

CeloNova BioSciences, Inc. | April 08, 2022

CeloNova BioSciences, Inc. developer and manufacturer of a portfolio of novel surfaced coated technologies, including the proprietary Polyzene™-F nanocoating, announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimize implant interaction within the body. The company's nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date. "We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects," stated Carl St. Bernard, President and Chief Executive Officer of CeloNova. "This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies." "I fully support CeloNova's new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F. When my students and I set out to study the hemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realized its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices." Professor Dr. Michael Grunze, Former Chair and Professor (emeritus) at the Institute of Applied Physical Chemistry of the Ruprecht-Karls-University in Heidelberg and co-inventor of Polyzene-F CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the U.S. and the EU. The company's PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated Coronary Stent, was developed to safely and effectively treat patients who may benefit from 1-month of dual antiplatelet therapy. CeloNova's new business direction builds upon the successful application of PzF in interventional oncology and cardiology and expands its opportunities through the development of new surface coating technologies to address important unmet clinical needs. "In my pre-clinical research at CVPath since 2012, CeloNova's proprietary Polyzene-F coating has consistently demonstrated a unique advantage of allowing an implant to heal quickly and in a functional way, without the need for antiproliferative drug elution," stated Aloke Finn, MD, Medical Director and Chief Scientific Officer at CVPath and Associate Professor of Medicine at the University of Maryland. "I believe Polyzene-F will continue to play an important role in delivering safety and efficacy in clinical practice." Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.1* About CeloNova BioSciences, Inc. CeloNova BioSciences, Inc. is a global medical device company that develops, manufactures and markets novel surfaced coated technologies, including its proprietary Polyzene™-F nanocoating. The next generation nanocoating is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date.

Read More

FUTURE OF HEALTHCARE

Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products

Endonovo Therapeutics, Inc. | April 26, 2022

Endonovo Therapeutics, Inc. announced an agreement with NAMSA – a leading Global Contract Research Organization and medical device reimbursement specialist – as strategic advisors to develop in-patient and out-patient medical reimbursement strategies for Endonovo’s flagship PEMF product SofPulse®. “Engaging NAMSA as strategy advisors to develop and apply proven medical device reimbursement strategies is a huge advantage for Endonovo and our shareholders, according to Endonovo CEO Alan Collier. “NAMSA is a proven medical device development partner with relevant therapeutic know-how that is critical when seeking acceleration of reimbursement efforts and commercialization objectives,” he pointed out. NAMSA was founded in 1967 as a scientific research company and later transitioned into a Global CRO and Medtech (Medical Technologies) reimbursement specialist. Today, it has 1,000 strategic associates who provide Medtech reimbursement advisory expertise to more than 300 clients in 15 global regions. NAMSA offers a full continuum of reimbursement services for medical technologies. Their reimbursement consultants provide: payer relations, medical policy research, coverage advocacy, Healthcare Common Procedure Coding System Current Procedural Terminology code analysis/applications and health economic analysis. “Our team strives to bring impactful products like the Endonovo SofPulse into higher adoption. With this technology, and its favorable economics, there are multiple opportunities ahead for serving populations in need. We will work together with the Endonovo team to improve market access for this novel device in the very near term.”, Joseph Sierra, Director, Reimbursement Consulting, North America, NAMSA NAMSA provides strategic guidance and tactical support to fast-track medical device commercialization and to make an immediate impact on patient healthcare worldwide. NAMSA’s services have grown to include regulatory, reimbursement and quality consulting as well as clinical research. These additions have helped NAMSA to become the pre-eminent 100% medical device-focused Global CRO that offers proven strategic solutions throughout the full development continuum. NAMSA is the only US FDA ASCA accredited medical device biocompatibility laboratory in the world. This allows medical device sponsors to fast-track commercialization efforts, while achieving time and cost efficiencies in every major market of the world. Collier stated: “We are fortunate to be working directly with Joseph Sierra, at NAMSA. With over 10 years of reimbursement experience, and his proven track-record in developing successful medical device reimbursement strategies is exemplary and will be helpful in developing the path toward reimbursement for our main product SofPulse®. Joseph is an adjunct instructor at USC Masters of Health Administration Program, and his prior professional work includes successful stints with NeoFect USA and Medtronic Ltd. where he demonstrated a record of success leading roles in reimbursement programs, analysis, and strategies for their medical devices.” NAMSA’s reimbursement expertise and track-record in the introduction and adoption of medical devices into multiple medical specialties includes: orthopedics, cardiovascular surgery, general surgery, plastic surgery, neurology, robotic surgery and wound care. Collaborating with NAMSA on global reimbursement allows Endonovo to explore reimbursement for the U.S. medical markets as well as the European Union market adoption through SofPulse® medical CE Mark. Additional target markets would be Taiwan and other Asian countries. About Endonovo Therapeutics Inc. Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices for pain relief, general wellness and wound curatives. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system disorders, including traumatic brain injury, acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema. It also has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease, non-alcoholic steatohepatitis cardiovascular and peripheral artery disease and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Read More

HEALTH TECHNOLOGY

InfuSystem Announces Master Service Agreement with Leading Global Healthcare Technology and Diagnostic Company

InfuSystem Holdings, Inc. | April 29, 2022

InfuSystem Holdings, Inc. a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today it has entered into a three-year master service agreement with a leading global healthcare technology and diagnostic company, effective April 25, 2022. As part of the master service agreement, InfuSystem will be providing its biomedical services, which include annual preventative maintenance and repair solutions, to a majority of the fleet of infusion pumps at hospitals and other medical facilities under contract with this tier one global healthcare company. Service will be conducted on-site at the acute care facility or off-site at one of InfuSystem’s seven service centers. This global healthcare technology and diagnostic company’s preferred customers’ infusion pump fleet consists of more than 300,000 pumps located in 1,200 medical facilities, including 800 hospital systems in the U.S. and Canada. This preferred national service agreement is estimated to generate approximately $10 to $12 million, after an initial ramp-up period, in annual revenue under InfuSystem’s DME service platform. “I am extremely pleased the tier one global healthcare company has entrusted InfuSystem to be their preferred national service provider. We will deliver our 'white glove' biomedical services for their infusion pump fleet throughout North America. This master service agreement could potentially lead to additional opportunities to serve this customer to provide other products and services we offer under our DME Services segment. The wide-ranging expertise and capabilities of our DME platform, along with our proven track record of industry-leading service, and our national network of service centers, were important factors in their decision to partner with InfuSystem.” Richard DiIorio, Chief Executive Officer of InfuSystem “This acute care service opportunity is the direct result of effectively integrating our biomedical services acquisitions and creating a highly effective operating unit to service tier one clients in order to drive growth and significantly expand market share. Our certified biomedical service teams will be deployed throughout North America to commence onboarding of the global healthcare company’s infusion fleet, and to conduct service and repairs on-site or at one of our national service centers. I believe this preferred national service agreement lays the foundation for long-term growth of our DME business and even greater expansion into the acute care space.” “This master service agreement represents a significant milestone for the Company. It is a testament to our team’s hard work and dedication in providing industry-leading service and repair solutions. We look forward to a long and successful relationship for years to come,” concluded Mr. DiIorio. About InfuSystem Holdings, Inc. InfuSystem Holdings, Inc. is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, Wound Therapy and Lymphedema businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients. The DME Services segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Read More

Spotlight

The World Health Organization (WHO) has called the West Africa Ebola outbreak an international public health emergency. This infographic presents the public health benefits of using ICD-10 in the fight against Ebola. As the fourth American Ebola patient, a physician serving in West Africa, was flown to the U.S. for emergency care this week, I was reminded that public health also wins from the implementation of ICD-10. According to World Health Organization (WHO), the latest Ebola outbreak has killed almost 2,300 people in five West African countries. Medical workers have been hit hard by the Ebola epidemic.

Resources